
EU approves daraxonrasib as first targeted pill for advanced pancreatic cancer
The European Commission has approved daraxonrasib, a daily pill targeting KRAS mutations, for advanced pancreatic cancer. While early trials show tumours shrinking or vanishing in some patients, experts warn it is not a cure and longer studies are needed to confirm survival benefits.
